Top Industry Leaders in the Dyspepsia Market
Latest Dyspepsia Companies Update
January 2023: A licensing agreement has been announced by MetaMe Health, a manufacturer of prescription digital therapeutics (PDT), for a novel gut-directed hypnotherapy program designed to treat functional dyspepsia. The agreement could potentially provide the company, which is presently engaged in the development of pharmaceuticals for gastrointestinal disorders, with access to a significant market. Even during or after meals, functional dyspepsia is a chronic disorder of the upper gastrointestinal tract characterized by abdominal pain, indigestion, nausea, and a feeling of fullness or bloating. It is diagnosed when there is no other obvious cause for the patient's symptoms. Although the digestive disorder is estimated to affect one in ten individuals, MetaMe Health asserts that functional dyspepsia is difficult to treat due to the lack of consistently effective medications.
May 2022: The US Food and Drug Administration (FDA) approved MounjaroTM (tirzepatide) injection, a once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist developed by Eli Lilly and Company. The drug was approved in May 2022 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Mounjaro is not recommended for patients with type 1 diabetes mellitus and has not been studied in individuals with a history of pancreatitis. Mounjaro, the first and only GLP-1 receptor agonist to receive FDA approval, functions as an endogenous incretin hormone receptor activator via a single molecule. Throughout the SURPASS program, which was designed to evaluate the efficacy and safety of Mounjaro in a diverse group of individuals with type 2 diabetes who may be treated in clinical practice, it outperformed all comparators in terms of A1C reductions.List of Dyspepsia Key companies in the market
- AstraZeneca
- GlaxoSmithKline
- Takeda Pharmaceutical Company
- Johnson & Johnson
- Eisai Co., Ltd
- Abbott Laboratories
- Salix Pharmaceuticals
- Bayer AG
- Boehringer Ingelheim GmbH
- Sanofi
- Allergan Plc